Kite Pharma (KITE) volatility at 104 into lymphoma drug trial meets primary endpoint

Kite Pharma (NASDAQ: KITE) is recently up $7.52 to $62.50 in the premarket after the cancer researcher reported data from an early analysis of its lead drug candidate KTE-C19, which met its goal of meaningfully shrinking tumors. Option implied volatility index mean is at 104, compared to its 52-week range of 51 to 117, according to Livevol.

You May Also Be Interested In

• Tesla (TSLA) call put ratio 1 call to 1.1 puts into quarter results
• Hasbro (HAS) May option implied volatility into quarter results
• Boeing (BA) April weekly option implied volatility into quarter results